Welcome
About Foamix
Our Team
Our Advisors
Technologies
Emollient Foamix™
OleoFoamix™
Suspension Foam™
Waterless Foam™
OILGEL™
Products
DermaFoamix™
Dermatological Product Pipeline
CosmetoFoamix™
Cosmetic Product Pipeline
GyneFoamix™
Strategy
Contact
News
Press Releases
Press Coverage
Useful Links
Press Releases
31/05/2010
Foamix to present at the UBS 2010 Global Specialty Pharmaceuticals Conference
20/05/2010
New U.S. Patent Grant to Foamix for its Hygroscopic and Waterless Breakable Foam Technology
29/04/2010
Foamix Receives a New U.S. Patent for its Emollient and Aqueous Foam Technology
26/04/2010
Foamix is Granted a Fourth U.S. Patent for OilGel™, Directed to Pharmaceutical Compositions and their Dermatological, Gynecological and Ophthalmic Applications
03/03/2010
Foamix Ltd. and Therapeutics Inc. Enter into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases
04/01/2010
US Grant for Foamix's Saccharide Foam Patent Adds Depth to Foamix's Broad Intellectual Portfolio and Protects Topical "Sweet Foam" Products for Wound & Burn Therapy
04/01/2010
Foamix is a Finalist for the Red Herring 100 Global Award for Most Promising Technology Ventures
04/11/2009
Foamix Expands International Patent Protection for its Emollient Foam Platform
03/11/2009
Foamix Extends Collaboration with Galderma
02/02/2009
Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis
28/01/2009
Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis
08/12/2008
Foamix is Finalist for International 2008 SCRIP Award
03/06/2008
Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
13/05/2008
Omnibus Survey: 72% of Women Are Dissatisfied with Their Current Treatment of Vaginal Infection
29/04/2008
Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
26/03/2008
Foamix is a Finalist for the Red Herring 100 Europe 2008 Award
13/11/2007
Foamix Announces New Foam Patent Approvals
05/11/2007
Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
29/10/2007
Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology
09/07/2007
Foamix Presents Innovative Intra-Vaginal Foam Delivery for Gynecology
24/01/2007
Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam
20/01/2007
Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product
10/01/2007
Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam
03/01/2007
Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne
24/07/2006
Foamix Announces New Waterless Foam Designed for Enhanced Skin Delivery - Useful for Steroids and Water Sensitive Drugs
20/07/2006
Foamix’s Betamethasone Foam Demonstrates High Efficacy in Psoriasis Treatment and 85% Better Usability than Cream in Phase I/II Study
17/07/2006
Foamix Names David Schuz as Senior Vice President, Intellectual Property.
29/03/2006
Foamix CEO to Present “The Changing Face of Dermatology” at the Bio Business Forum at Bio International 2006 in Chicago, April 10, 2006
07/02/2006
Foamix Receives Patents for OilGel™ In the U.S. and in Australia
28/11/2005
Foamix Granted Third U.S. Patent for OilGel™, In Development for Dermatological and Ophthalmic Applications
03/11/2005
Foamix Executive Director Dr. Stanley Hirsch to Present
“Foamix - Innovative Delivery in Dermatology” at Bio-Europe 2005, November 8th at 8:30 a.m.
12/09/2005
Foamix Commences Phase II Study of
TerbiFoam™ 2% Foam
for the Treatment of Athlete’s Foot.
Company Concurrently Conducts Phase II Study of Betamethasone 0.12% Emollient Foam for the Treatment of Psoriasis
12/09/2005
Foamix to Showcase Emulsion-Based Cosmetic Foams at
The Health and Beauty America (HBA) Conference in New York
18/07/2005
Foamix’s PerFoam™ for the Treatment of Lice Demonstrates Safety and 96% Efficacy in Phase II/III Study
08/06/2005
Foamix Selected to Present at the Bio Business Forum at Bio International 2005 in Philadelphia in June
06/02/2005
Foamix "Breaks the Ribbon" on New Facility
04/02/2005
Foamix Unveils Unique Mupirocin Foam
02/06/2004
Foamix Unveils Innovative Vaginal Foam
15/09/2003
Phase II Psoriasis Study Approved
10/06/2003
Foamix Unveils Revolutionary Dermatological Foams